Socioeconomic disparities in IDH-wildtype glioblastoma survival: interactions between age and household income in a SEER cohort
Journal of Neuro-Oncology · 2026
DOI: 10.1007/s11060-026-05504-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2026. Verfasst von Ying Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery and National Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Central South University, Changsha, 41000…. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Income, Isocitrate Dehydrogenase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Glioblastoma multiforme (GBM) remains an aggressive brain tumor with a poor prognosis. The financial burden of GBM have raised concerns about accessibility and equity in care. We performed a cohort study to evaluate the impact of household income on survival outcomes in patients with IDH-wildtype GBM. METHODS: Patients diagnosed with IDH-wildtype GBM from 2018 to 2021 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database and categorized into low-, middle-, and high-income groups based on household income. Univariate and multivariate Cox regression models were used to analyze survival data and evaluated by hazard ratios (HRs) and 95% confidence intervals (CI). Further analyses of interaction effects were also performed. RESULTS: In total, 6190 patients with IDH-wildtype GBM were included with a median survival of 12.52 months. Multivariate analysis revealed that middle- and high-income patients had significantly better survival outcomes compared to low-income patients (overall survival: HR 0.881 (0.816-0.951), p = 0.001, HR 0.860 (0.792-0.934), p < 0.001; GBM-specific survival: HR 0.866 (0.799-0.937), p < 0.001, HR 0.854 (0.784-0.929), p < 0.001). Such disparities in survival widened over time, particularly for GBM-specific survival. An interaction effect was also found between household income and age, with older, low-income patients with IDH-wildtype GBM showing significantly worse outcomes. CONCLUSION: Household income is an independent predictor of survival in patients with IDH-wildtype GBM. Disparities in outcomes are widening over time, and targeted interventions are needed to address the socioeconomic barriers to treatment, particularly for older, low-income patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery and National Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Central South University, Changsha, 410008, China.
- Teaching and Research Section of Clinical Nursing, Xiangya Hospital, Central South University, Changsha, 410008, China. 254516709@qq.com.
- Department of Neurosurgery and National Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Central South University, Changsha, 410008, China. zhanglb@csu.edu.cn.
- Department of Neurosurgery, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, 330000, China. zhanglb@csu.edu.cn.
Zitieren
APA
Wang, Y., Xie, K., Yang, K., Luo, A., & Zhang, L. (2026). Socioeconomic disparities in IDH-wildtype glioblastoma survival: interactions between age and household income in a SEER cohort. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-026-05504-8
Vancouver
Wang Y, Xie K, Yang K, Luo A, Zhang L. Socioeconomic disparities in IDH-wildtype glioblastoma survival: interactions between age and household income in a SEER cohort. Journal of Neuro-Oncology. 2026. doi:10.1007/s11060-026-05504-8
BibTeX
@article{Wang2026,
author = {Wang, Ying and Xie, Kang and Yang, Kang and Luo, Aihong and Zhang, Longbo},
title = {Socioeconomic disparities in IDH-wildtype glioblastoma survival: interactions between age and household income in a SEER cohort},
journal = {Journal of Neuro-Oncology},
year = {2026},
doi = {10.1007/s11060-026-05504-8}
}
EUVIMED